Biosion, Inc.

Biosion is a clinical-stage global biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® high-throughput endocytosis platform, and Flexibody™ bispecific platform. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in Phase 2 for severe asthma and entering Phase 2 for atopic dermatitis. Biosion and partners have plans to progress additional immune-oncology biologics and antibody drug conjugates into clinical trials for oncology indications over the next three years. Biosion has operations in the US, Australia, and China.